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Abstract 
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system. The disease is 
characterised by inflammation with extensive immune infiltration, demyelination, axonal loss and damage of oligodendrocytes, 
presumably auto-immune in nature. The influence of environmental factors on the development and activity of MS has been 
known for a long time. Vitamin D and sun exposure are among the most important ones. Both serum vitamin D level and sun 
exposure independent of vitamin D production are correlated with epidemiological and clinical parameters of MS, and the 
impact of vitamin D on immune parameters has been clearly confirmed in experimental studies. Nevertheless, the impact on 
clinical aspects is inconclusive, especially when the influence of supplementation is assessed. In this work we review the state 
of knowledge regarding the effect of vitamin D on immune cells subsets in relation to experimental and clinical studies.
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Multiple sclerosis (MS) is a chronic inflammatory and neu-
rodegenerative disorder of the central nervous system (CNS). 
The disease is characterised by inflammation with extensive 
immune infiltration, demyelination, axonal loss and damage of 
oligodendrocytes. The precise cause of MS remains unknown, 
but it is considered to be an autoimmune disease. A key role 
is played by T-lymphocytes, which after activation outside of 
the CNS pass through the blood-brain-barrier (BBB). T cells 
can contribute to CNS damage directly via cell-cell death or 
via soluble mediators including cytokines or proteases. Many 
studies suggest that B cells are equally important in MS patho-
genesis. The presence of immunoglobulinG oligoclonal bands 
in the cerebrospinal fluid (CSF) of MS patients is a biomarker 
for disease and antibodies play a crucial role for demyelina-
tion in experimental autoimmune encephalomyelitis (EAE) 
[1]. The prevalence of MS is greater at higher latitudes, and 
tends to peak in areas with fewer sunny days. Traditionally, 
this prevalence was explained by a low exposure to ultravio-
let light and/or diet, but several studies have shown that it 
is mainly the result of a lack or small amount of vitamin D 
[2, 3]. Vitamin D is an immunomodulator affecting both the 
innate and the adaptive immune system which is important 
in the development and activity of MS. The impact of vitamin 
D on immune parameters is evident in vitro, while the effects 
on the clinical aspects are inconclusive, especially when the 
effect of supplementation is assessed. In this work, we review 
current knowledge on the effect of vitamin D on immune 
cells subsets in relation to in vitro and in vivo studies. In this 
review, the term ‘vitamin D’ is used in relation to 25(OH)D 
or 1,25(OH)2D3, unless otherwise stated. 
Vitamin D
Vitamin D is a pro-hormone belonging to the category of 
fat-soluble group of vitamins. It is primarily responsible for 
maintaining calcium homeostasis by facilitating absorption 
and utilisation of minerals and acts toward bone formation and 
homeostasis [4, 5]. This vitamin has also a much broader effect, 
as evidenced by the presence of its receptor in many organs 
and tissues [6]. The main sources of vitamin D are sunlight, 
diet, and supplementation. Vitamin D in the skin is present 
in the form of pro- vitamin D3 (7-dehydrocholesterol) and is 
converted to pre-vitamin D3 photochemically by ultraviolet 
B (UV-B) rays from the sun and subsequently converted to 
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vitamin D3 by isomerisation. Foods rich in vitamin D include 
fatty fish (e.g. salmon, mackerel), cod liver oil, and, in small 
amounts, eggs. Relative to sun exposure, diet is a poor source of 
vitamin D. Vitamin D3 from the skin, food, or supplements is 
transported to the liver by vitamin D–binding proteins, where 
it is converted to 25(OH)D3 (calcidiol) through the process of 
hydroxylation. In the kidneys, 25(OH)D3 goes through a se-
cond hydroxylation to 1,25(OH)2D3 (calcitriol) which is the 
active metabolite. 1,25(OH)2D3 mediates its biological effects 
by binding to intracellular vitamin D receptor (VDR), which is 
a nuclear receptor that acts as a transcription factor. The bin-
ding 1,25(OH)2D3 with VDR leads to its heterodimerisation 
with the retinoid-X receptor (RXR), resulting in modulation 
of vitamin D responsive gene expression by translocation of 
heterodimer complex (1, 25 (OH)2D3-VDR/RXR) to nucleus, 
and its recruitment on vitamin D response elements (VDRE) 
of target genes. Depending on the site of recruitment of VDR, 
1,25(OH)2D3 may regulate protein expression of target vita-
min D-sensitive genes involved in diverse cellular processes.
This includes cellular growth, proliferation, differentiation, 
apoptosis, oxidative stress and membrane transport [4, 6, 
7]. A detailed review of the relationship between VDR and 
immune cells in multiple sclerosis was presented recently by 
Lu et al [8]. Thus, vitamin D affects the metabolism of various 
tissues and also has a significant influence both on innate and 
adaptive immunity. Because all immune cells express VDR, 
(e.g. macrophages, dendritic cells, T cells and B cells), vitamin 
D’s effect on immunity via VDR leads to a shift in the immune 
response toward anti-inflammatory [7–9]. 
Impact of vitamin D on immunity cells
Dendritic cells (DCs) — Dendritic cells are the main 
antigen-presenting cells (APCs). Their function is to take 
up foreign antigens and present them as peptides to T cells 
on the human leukocyte antigen (HLA) molecules. DCs are 
predominantly found in an immature state in peripheral tis-
sues. Upon encountering a foreign antigen, they mature and 
migrate to the lymphoid tissues to stimulate antigen-specific 
T cells. Depending on the cytokines secreted by the DC, the 
T cells will differentiate into effector cells with appropriate 
pro- or anti-inflammatory properties [10]. As ‘professional’ 
APCs, DCs play a key role in the pathogenesis of MS and 
EAE, in both mediating immune responses and inducing 
immune tolerance [11]. DCs constitutively express VDR and 
in the presence of 1,25(OH)2D3 remain in an immature-like 
tolerogenic state. This is characterised by inhibiting upregu-
lation of the expression of MHC class II, CD40, CD80, and 
CD86 plus decreased production of pro-inflammatory IL-
12 and TNFα and increased anti-inflammatory IL-10 produc-
tion. 1,25(OH)2D3 can only induce this tolerogenic phenotype 
in DCs when it is added before their maturation [12, 13]. These 
tolerogenic DCs induce the differentiation of T regulatory 
(Treg) cells. Furthermore, they specifically induce apoptosis 
in autoreactive T cells, while not affecting the proliferation of 
other T cells [14, 15].  In vitro studies have confirmed that vita-
min D inhibits DCs differentiation and maturation. However, 
the mechanism of Treg induction by DCs is not entirely clear. 
Recent studies have indicated that this depends on the type 
of DCs and there may be various mechanisms leading to the 
formation of Treg [16]. In EAE, both in vivo administration 
of vitamin D, and transfer of vitamin D-induced tolerogenic 
DCs, leads to a significant increase in the percentage of CD4(+) 
CD25(+) Foxp3(+) regulatory T cells and IL 10 production, 
as well as a decrease in the number of autoreactive T cells. 
Moreover, it significantly decreased the incidence of EAE 
and also reduced its severity [17–19]. Tolerogenic DCs are 
a very interesting direction of therapeutic research in MS, 
and currently the use of tolerogenic DCs generated with 
1,25(OH)2D3 is being tested [20].
 Macrophages — Macrophages are main phagocytic cells 
and they are also important APCs. In a normal immune 
response, they produce inflammatory mediators and recruit 
other immune cells to eradicate the pathogen. Macrophages 
can be divided into two categories: M1 and M2 macrophages. 
M1 macrophages produce pro-inflammatory mediators such as 
nitric oxide, TNFα, IL-23, IL-12, and IL-1β, whereby they kill 
pathogens and promote the polarisation of T helper (Th) cells 
to proinflammatory T helper 1 and 17 cells (Th1, Th17). On the 
other hand, M2 macrophages produce the anti-inflammatory 
cytokine IL-10 and are important in wound repair and restor-
ing tissue homeostasis. In autoimmune diseases, macrophages 
are hyperactivated and produce more pro-inflammatory cy-
tokines, suggesting a dysregulated balance between M1 and 
M2 cells [16, 21]. Vitamin D has dual roles in the differentia-
tion and activation of macrophages. In the early stages of in-
fection, 1,25(OH)2D3 stimulates differentiation of monocytes 
into macrophages and enhances the antimicrobial activity of 
human monocytes and macrophages. This pathway is vitamin 
D dependent and is not induced if the level of vitamin D is not 
sufficient [21–24]. Vitamin D also promotes the production 
of anti-inflammatory IL-10 and decreases the production of 
pro-inflammatory IL-1β, IL-6, TNFα, RANKL, COX-2, and 
nitric oxide. Finally, 1,25(OH)2D3-treated macrophages have 
been shown to reduce T cell stimulatory capacity [16, 22, 24]. 
In EAE, Nashold et al showed that vitamin D decreases macro-
phage accumulation in the CNS of mice, but flow cytometric 
analysis detected no significant differences between the groups 
with or without vitamin D suplementation, with respect to T 
cells or B cells or macrophages in draining lymph nodes or 
spinal cords [25].
T cells —  T-cells consist of different subgroups such 
as CD4+ T-helper cells, cytotoxic CD8+ T-cells, regulatory 
T-cells, natural killer T cells (NKT) and gamma-delta T-cells. 
Currently, it is hypothesised that an imbalance between 
pro-inflammatory Th1/Th17 cells and Tregs is the crucial 
factor in the immunopathogenesis of MS. Vitamin D may 
act by restoring this balance, thereby restoring immune 
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homeostasis. This is related to the presence of VDR on 
Tcells [1, 26]. 
CD4+ T Cells
Th1 and Th2 - Classically, CD4+ T cells were subdivided 
into two classes: Th1 cells (with proinflamatory proper-
ties) and Th2 cells (with anti-inflammatory properties). 
1,25(OH)2D3 inhibits the proliferation and differentiation 
of Th1 cells and enhances the expression of PD1, PD-L1 and 
CTLA4, inhibitory markers on CD4+. In addition, it suppresses 
the production of proinflammatory cytokines mediated by 
Th1 cells and reduces IL-2, IL-6, IFN-γ, IL-17, and IL-22 secre-
tion [24].  On the other hand, the activity of immune responses 
mediated by Th2 cells including the secretion of IL-3, IL-4, 
IL-5, IL-10, IL-13 has been enhanced by vitamin D. 
It has been suggested that the impact of vitamin D on 
immune reactions is by promoting the Th2 cells response and 
suppressing the Th1 cells immune activity [26–28]. In EAE, 
vitamin D affects Th1 and Th2 cells and Th1/Th2 cytokine 
synthesis inhibiting EAE induction and significantly decreases 
its activity [17, 29–31]. Mayne et al showed that vitamin D 
acts directly on pathogenic CD4(+) T cells to inhibit EAE 
through the nuclear VDR. Vitamin D failed to inhibit EAE 
disease induction in chimeric mice lacking a functional VDR 
in haematopoietic cells and in T lymphocytes [30]. In another 
study, 1,25(OH)2D3 treatment significantly reduced the clini-
cal severity of EAE within three days, decreasing chemokines 
levels and monocyte trafficking [31]. Studies carried out in 
MS patients have had ambiguous results. Mahon found that 
vitamin D supplementation significantly increased serum 
transforming growth factor-beta. Tumour necrosis factor 
(TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-
13 were not different following vitamin D supplementation 
[32]. However, an open-label randomised prospective con-
trolled 52-week trial in patients with MS treated with escalating 
vitamin D doses up to 40,000 IU/day over 28 weeks showed 
that T-cell reactivity and proliferation dropped significantly in 
treated patients over the treatment period, while no change was 
seen in controls. However, cytokines profiles did not change 
significantly during the study [33]. A similar result was found 
in a study with a short term (24 weeks) supplementation of 
vitamin D in patients with clinically isolated syndrome (CIS) 
and controls. No significant differences were observed in the 
concentrations of IL-10, IL-17 and IFN-gamma produced 
followed stimulation of peripheral blood mononuclear cells 
(PBMCs) in any treatment arm. Moreover, no significant re-
duction in the frequency of proinflammatory CD4 T cells was 
seen [34]. Only Ashtari et al showed that in RRMS patients 
IL-10 serum level increased significantly after taking high-dose 
vitamin D3 for three months [35].
Th17 Cells - In most autoimmune diseases, Th17 cells are 
considered to be important drivers of disease pathogenesis. 
Th17 cells have proinflammatory properties and are charac-
terised by the production of cytokines such as IL-17A, IL-17F, 
TNFα, proinflammatory cytokine granulocyte macrophage 
colony–stimulating factor (GM-CSF) and expression of the 
specific transcription factor, retinoid related orphan receptor 
(ROR). They can also be distinguished based on the expression 
of the chemokine receptor CCR6, which directs migration 
toward the chemokine CCL20. Their differentiation can be 
driven by TGFβ, IL-6, and IL-1β, but they require IL-23 to 
become pathogenic Th17 cells [36, 37]. 
Together, Th1 and Th17 effector cells are considered to be 
the major inflammatory mediators in MS. Notably, MS serum 
levels of IL-17 correlate with disease severity [38]. Vitamin 
D inhibits the differentiation and activity of Th17 cells. The 
presence of 1,25(OH)2D3 inhibits differentiation naïve CD4+ 
T cells toward the Th17 lineage in vitro and the formation of 
Th17-related cytokines and transcription factors such as IL-
17A, IL-17F, RORC, and CCR6 [16, 39]. Similar results have 
been reported in the EAE model. Mice treated with vitamin D 
had fewer Th17cells and lower IL-17 production than placebo 
controls. This was related to a reduction of EAE induction and 
activity [40, 41]. Recently, vitamin D’s impact on the expression 
of some Th17 cell- related cytokines, chemokines and che-
mokine receptors was investigated in EAE. In EAE mice, the 
expression of IL-17, IL-23 P19, IL-23 P40, CCL20, CCL22 and 
CCR4 in spinal cord and IL-17 and IL-23 serum levels were 
significantly higher than that in the control group [42]. The 
results are not conclusive in patients with MS. Da Costa et al 
evaluated in vitro the ability of 1,25(OH)2D in modulating dif-
ferent Th17 cell subsets in MS patients in the remission phase. 
The 1,25(OH)2D reduced Th17-related cytokines (IL-1β, IL-6, 
IL-17, IL-22), as well as GM-CSF. Additionally, the proportion 
of both IL17+/IFNγ+ (CD4+ and CD8+) T cells and IL17+/
IFNγ- CD8+ T cells was positively related with neurological 
symptoms, determined by EDSS score [43]. Also Bhargava et 
al demonstrated that vitamin D supplementation decreased 
IL-17 producing CD4+ T cells and effector-memory CD4+ 
T-cells in MS patients [44]. However, Smolders et al found 
no correlation between Th17 cells and vitamin D serum level 
in MS patients [45]. Moreover, a high dose of oral vitamin 
D3 supplementation did not affect Th17 cells in MS patients 
[46]. Additionally, a randomised, double-blind, placebo-
controlled clinical trial did not show a significant decrease of 
serum IL 17 level after 12 weeks of vitamin D supplementa-
tion. This was a small study (94 patients) and vitamin D was 
an added therapy to IFN-beta treatment [47].
Similarly, a sub-study of a larger clinical trial exploring 
high dose (up to 14,000 IU/day) vitamin D supplementation, 
as an add-on therapy to interferon beta 1a in patients with 
RRMS, showed no difference in either IL-17 CD4+ or IFN-
gamma CD4+ T cells at 48 weeks of observation [48]. 
Regulatory T cells (Tregs) - suppress the immune response. 
Tregs express forkhead transcription factor FoxP3 which has 
been identified as essential in preventing autoimmunity in 
several animal models. Additionally, T regulatory cells se-
crete anti-inflammatory cytokines IL-10, IL-35, transforming 
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in the CSF of patients with MS, complement deposition in 
type II lesions in CNS and B cell follicular structures in the 
meninges. Moreover, they can play several different roles: 
production of autoantibodies, formation of B-cell follicles with 
germinal centre activity, antigen presentation, production of 
pro-inflammatory cytokines, and anti-inflammatory immune 
regulation (Breg cells) [1, 58]. 
The effect of vitamin D on B cells is still not completely 
clear. Several studies have suggested that vitamin D reduces 
the proliferation of B cells, induces their apoptosis, and 
decreases antibody production. Moreover, it has been shown 
that vitamin D promotes IL-10 production in human B cells 
[59–61]. Currently, the effect of vitamin D on the proliferation 
and function of B cells in MS is being discussed. It has been 
shown that in vitro vitamin D has several effects on B cells, 
which may be beneficial in MS: the inhibition of plasma cell 
generation, the inhibition of T-cell co-stimulation, and the 
enhancement of Breg cell activity [62]. Unfortunately, the 
inhibitory effects of vitamin D have not been confirmed in 
vivo. Despite a 12-week high-dose vitamin D supplementation 
and a significant increase in serum vitamin D level, a shift 
in B cell differentiation was not found. IgG levels in serum 
and CSF of patients with MS did not correlate with 25(OH)
D concentrations [63]. Also, after 12 weeks of high dose vi-
tamin D supplementation, patients with RRMS did not show 
differences in total plasma IgG and IgM levels [64]. Likewise, 
in a cohort of healthy controls and RRMS patients, there was 
no correlation between IL-10 producing B cells and serum 
vitamin D level [65].
Impact of vitamin D on clinical  
activity of MS
Vitamin D’s impact on immunity in MS patients has been 
confirmed in many in vitro studies. 
Also studies in EAE strongly suggest the protective role 
of vitamin D [16]. However, the results of a small number 
of clinical trials exploring various immunological outcomes 
in response to vitamin D supplementation in MS have been 
contradictory.  On the basis of current data, it is difficult 
to determine the molecular immunological mechanism of 
vitamin D supplementation. It is not clear why human data 
are conflicting, but vitamin D3 status at enrollment, vitamin 
D3 dose, dose frequency, use of disease-modifying drugs, and 
the timing of sampling (season, oestrogen cycling in women) 
are all potential confounding factors. This is an interesting 
problem, because a similar situation was encountered when 
the assessment of MS clinical activity after vitamin D supple-
mentation was evaluated. Several studies have consistently 
shown an inverse relationship between vitamin D levels and 
the frequency of relapses, disability progression, and occur-
rence of new brain MRI lesions [39]. 
However, the evaluation of these parameters after vitamin 
D supplementation has yielded conflicting results. These 
growth factor-b (TGF-b), the inhibitory co-receptor CTLA4, 
and a high level of CD25 [39, 49]. They exert immunomodu-
latory effects on other immune cells such as macrophages, 
DCs, CD8+ T cells, and also other CD4+ T cells, thereby 
maintaining immune homeostasis [49]. In patients with 
MS, functional defects in FoxP3+CD4+ Treg cells have been 
described in peripheral blood T cells with a reduction of T 
cell immune response and a decrease of IL-10 production 
compared to controls [50, 51]. The impairment correlated 
with reduced FoxP3 expression in MS patient T cells [52]. 
In EAE, vitamin D induced the differentiation of Treg cells, 
while inhibiting Th1 and Th17 cell proliferation. In addition, 
1,25(OH)2D3 promoted secretion of the anti-inflammatory 
cytokine, transforming growth factor beta1 (TGF-β1) but sup-
pressed pro-inflammatory cytokines such as IL-17 [43, 49, 53].
Spanier et al found, interestingly, that vitamin D acts 
synergistically with oestrogen, causing a decreased EAE risk 
in a female-biased manner. Moreover, a synergistic impact 
of vitamin D and oestrogen in VDR-expressing CD4(+) T 
is essential to induce Helios(+)FoxP3(+) T cells and prevent 
autoimmune demyelinating disease [54]. This clinical study 
only partially confirmed the impact of vitamin D on Treg in 
MS patients. 
One study showed that the capacity of the CD25+CD4+ 
Treg cells was correlated with serum 25-OHD levels in MS 
patients [45], although this association could not be substan-
tiated upon vitamin D3 supplementation [46].
CD8+ Cytotoxic T Cells
CD8+ T cells contribute to the immune response by indu-
cing apoptosis in abnormal cells in cases of infection or cancer, 
and CD8+ T cells have a higher expression of VDR than CD4+ 
T cells [9, 51]. In MS, CD8 T cells are the most frequent T cell 
subset in acute and chronic plaques. Moreover, oligoclonal 
expansion of CD8 cells were observed in CSF, and the blood 
of MS patients [55, 56]. Nevertheless, in EAE, Nashold et al 
detected no significant differences between the groups with 
or without vitamin D suplementation, with respect to CD4+ 
or CD8+ cells in draining lymph nodes or spinal cord [25]. 
In MS patients, Lysandropulos found that vitamin D can act 
directly on CD8+ T cells [50], and with 1,25(OH)2D3, CD8+ 
cells secreted less IFN-gamma and TNF-alpha and more 
IL-5 and TGF-beta [57]. 
B Cells
B cells play a crucial role in the immune response by the 
production of autoreactive antibodies, modulating antigen 
presentation reaction and cytokine secretion. Human B cells 
are able to respond to vitamin D. They constitutively express 
low levels of the VDR, which is up-regulated upon B-cell 
stimulation [58]. 
In MS immunopathogenesis, B cells are important, so-
mething underlined by the presence of IgG oligoclonal bands 
117www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Halina Bartosik-Psujek, Marek Psujek, Vitamin D as an immune modulator in multiple sclerosis
results are difficult to compare because studies evaluating the 
effect of vitamin D supplementation on clinical parameters 
of MS have been generally small and with differing patterns. 
There have been studies with vitamin D alone, or with vitamin 
D as an add-on to a disease-modifying therapy, and highly 
varying doses of vitamin D have been used. 
Because of that, in this review we arediscussing only double 
blind, placebo-controlled, randomised trials. 
Stein et al investigated vitamin D’s effect in RRMS patients. 
In this six-month, double blind, placebo-controlled, randomi-
sed trial, participants received either 1,000 IU vitamin D daily 
(low-dose) or 6,000IU (high dose). The results from this study 
did not show any effect of vitamin D in terms of clinical and 
MRI parameters [66]. Also Kampman et al found that suple-
mentation of vitamin D did not result in beneficial effects on 
annualised relapse rates in a similar one-year, double-blind, 
placebo-controlled, randomised study in 66 MS patients [67]. 
Soilu-Hänninen et al did not find a reduction in the annual 
relapse rate although there was a tendency toward reduced 
disability accumulation as measured by EDSS and toward 
improved timed tandem walk. The authors stated that vitamin 
D add-on treatment to IFNbeta reduces MRI disease activity 
because patients in the vitamin D group showed fewer new 
T2 lesions and a significantly lower number of T1 enhan-
cing lesions [68]. SOLAR was a randomised, double-blind, 
placebo-controlled, multicentre, phase 2 study. In this study, 
229 patients were randomly assigned to vitamin D at a dose 
of 14,000 IU per day or a placebo as an add-on therapy to 
subcutaneous IFNbeta-1a. The percentage of patients with 
‘disease activity free’ status (defined as no relapses, no EDSS 
progression, and no new Gd+ or T2 MRI lesions) was intro-
duced as the primary endpoint. After 48 weeks of the study, 
no differences were found between the groups according to 
‘disease activity free’ status, annual relapse rate, or EDSS score. 
Only the MRI parameters showed a significant reduction of the 
number of new, combined, unique active lesions in the vitamin 
D group [69]. Likewise, only the MRI parameters showed a sig-
nificant reduction of the new or enlarged T1 and T2 lesions 
after vitamin D supplementation in another placebo-controlled 
study. In this study, 129 patients received 100,000 IU of vitamin 
D twice a month in addition to IFNbeta-1a over a 24-month 
period and no effect was found for clinical parameters [70]. 
Shaygannejad et al studied 50 patients in a 12-month, ran-
domised, double-blind, placebo-controlled study and the 
patients received either vitamin D 8,000IU/day or a placebo 
with a disease-modifying agent. Mosayebi et al evaluated the 
effects of vitamin D3 supplementation at a dose of 300,000 IU/
month vs placebo in 62 patients over a six-month period [71, 
72]. The authors did not find any beneficial effect of vitamin 
D supplementation either on the clinical or the MRI outcome 
in patients with RRMS [73]. 
Because the evidence for vitamin D as a treatment for MS 
is inconclusive, it is not surprising that a meta-analysis did not 
find a significant association between vitamin D supplemen-
tation and the clinical outcome [74, 75]. However, it is worth 
noting that the tendency towards a favourable clinical response 
Figure 1.  Sources, metabolism and potential immunomodulatory impact of vitamin D
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was associated with a higher level of vitamin D. This indicates 
the need to determine the level of vitamin D during treatment. 
This is especially important because Bhargava et al found that 
MS patients have a diminished serologic response to vitamin 
D supplementation compared to healthy controls and have 
a lower increase in vitamin D levels with supplementation [76]. 
The status of vitamin D as the main factor affecting the 
development and activity of MS is unproven. It is one of the 
multi-factorial impacts of the environment, which has recently 
been emphasised. A high importance has been attributed to 
UV radiation. 
It has been confirmed by epidemiological study that vita-
min D and sun exposure are additive independent risk factors 
for MS development. 
Further, the direct effects of sun exposure on MRI mea-
sures of neurodegeneration in MS, independently of vitamin 
D, have been reported [77, 78]. Studies in humans and mice 
suggest that UV radiation has an immunoregulatory property 
and this pathway is both vitamin D-dependent and vitamin 
D-independent [39, 79, 80]. The vitamin D-dependent pathway 
is considered the more important because humans obtain up to 
80% of their vitamin D through sun exposure. UVB photons 
initiate a pathway of vitamin D production, from 7-dehy-
drocholesterol to the active form of vitamin D, as described 
previously. Several reviews have covered the immunomodu-
latory properties of vitamin D, particularly with reference 
to the regulation of cells proposed as being important to the 
development of MS [1, 2, 16]. However, additional factors 
should be taken into account. Firstly, the immunomodu-
latory properties of 1,25(OH)2D are dependent on genetic 
variation of the vitamin D regulating genes, CYP27B1 and 
CYP24A1 [81]. Moreover, immune cells have the enzymes to 
directly convert provitamin D or 25(OH)D to 1,25(OH)2D, 
and local concentrations, at the level of the cells, may be much 
higher than systemic levels [2]. Also vitamin D may regulate 
VDR-expressing nonimmune cells in the CNS. In one study 
of CIS patients, each 25 nmol/L increase in vitamin level 
was significantly associated with 7.8 mL higher grey matter 
volume, and there was a trend for an inverse relationship over 
12 months between 25(OH)D levels and new brain lesions 
Table 1. Overview of randomised controlled trials with vitamin D supplementation and clinical outcome in multiple sclerosis 
Study Study design Supplementation 
dosage
Other medication 25(OH)D3 in 
treated group 
(nmol/L)
Clinical effect
Burton et al. (2010) 
[33]
Open, 52 weeks, 
Randomised 
49 MS pts (N = 25 
cholecalciferol, 
N = 24 placebo)
Escalating vitamin D3; 
4,000–40,000 IU/day 
(p.o) 
Control 4,000 IU vitamin 
D3/day
calcium 1,200 mg/day, conti-
nuation of DMT
Mean 413 No effect on EDSS
Trend toward redu-
ced relapse 
rate
Stein M et al. 
(2011) [66]
RCT, 6 months 
23 RRMS
 High dose (initial  
6,000 + 1,000 IU/day) 
vs low dose (1,000 IU/
day) vitamin D2. 
INF beta, GA Median  
High dose 120  
Low dose 69
↑EDSS and relapses 
in high dose group. 
No effect on T1Gd+ 
or T2 lesions
Mosayebi G et al. 
(2011) [72]
RCT, 6 months 
62 MS pts, 
N = 28 
cholecalciferol, 
N = 34 placebo
Vitamin D3 300,000 
IU/month (i.m)
INF beta 1a Mean ≈ 150 No effect on EDSS 
or Gd+ lesions
Soilu-Hänninen M 
et al. (2012) [68]
RCT, 12 months 
66 RRMS pts, (N = 34 
cholecalciferol, 
N = 32 placebo)
Vitamin D3 20,000 
IU/week (p.o)
INF beta 1b Mean 110 range 
(67–163)
↑T1Gd+ lesions 
No effect on T2 
lesions, 
EDSS or relapse
Kampman M et al. 
(2012) [67]
RCT, 96 weeks 
68 RRMS pts,  
(N = 35 
cholecalciferol, 
N = 33 placebo)
Vitamin D3 20,000 IU/
week (p.o)
Calcium 500 mg/day
 IFNbeta — 46% pts, GA 3% 
pts, natalizumab — 3% pts.
Mean 123 
(113–133)
No effect on relap-
se rate, EDSS, MSFC 
and fatigue
Shaygannejad V et 
al. (2012) [71] 
RCT, 12 months 
50 RRMS pts, (N-25 
calcitriol, 25 — pla-
cebo)
Escalating calcitriol: 
0.25–0.5 μg/day (p.o)
Continuation of DMT: IFN 
beta 86.0% pts, statins 10.0% 
pts, immunosuppressive 
drugs 4.0% pts. 
 No effect on EDSS 
or relapses
Golan et al. (2013) 
[73]
RCT, 12 months 
45 RRMS pts, ((N = 24 
cholecalciferol, 
N = 21 placebo)
Vitamin D3 4,370 IU/day, 
controls 800 IU/day
INF beta Mean  
High dose ≈ 120 
Low dose ≈ 50 
No effect on EDSS 
or relapses
DMT — disease-modifying therapy; EDSS — Expanded Disability Status Scale; GA — glatiramer acetate; Gd+ — gadolinium contrast enhancing lesions; IFNbeta — interferon beta; IU — International Units; 
MSCFC — Multiple Sclerosis Functional Composite; RCT — randomised controlled trial; RRMS — relapsing-remitting multiple sclerosis
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and clinical relapses [82]. Vitamin D-independent pathways 
can be modulated by several molecules: trans-urocanic acid 
in the stratum corneum, DNA, RNA, lipids and tryptophan 
of keratinocytes, and antigen-presenting cells. All may initiate 
pathways involved in signalling from skin to immune cells in 
draining lymph nodes and tissues beyond. It has been shown 
that sub-erythemal amounts of UVR, as in narrowband UV 
phototherapy, can suppress both local and systemic immunity, 
measured functionally by reduced cell-mediated immune 
responses [79, 80]. 
In sub-erythemal UV-irradiated skin there are produced 
cathelicidin LL-37 and the α- and β-defensins in the absence of 
any inflammation. These peptides have modest anti-microbial 
activity but rather pleiotropic immunoregulatory properties 
and β-defensins via induction of T-regulatory cells can prevent 
and mitigate EAE [83–85]. Other studies have also demon-
strated the effect of UV irradiation on an increase of Tregs and 
tolerogenic DCs both in EAE and in MS patients and in the 
maintenance of a pool of B-regulatory cells in the periphery 
[86, 87]. Recently, Breuer et al published a comprehensive 
review summarising the current knowledge regarding vitamin 
D and UVB light and concerning the clinical aspects of MS in 
epidemiological studies and clinical trials. The authors stressed 
that low vitamin D levels are associated with MS susceptibility 
and progression, although UVB light is involved in MS aetiol-
ogy and progression independent of vitamin D [88].
In conclusion, numerous studies have suggested that vi-
tamin D supplementation, and sun exposure independent of 
vitamin D production, may be protective against MS. 
However, none of these can be treated alone as an active 
and sufficient treatment in MS. Further research is needed to 
establish how and when individuals with CIS or MS should 
be supplemented and to elucidate the beneficial mechanism 
of actions of UV exposure. This could help us to identify new 
targets that could offer wholly new avenues of MS therapy. 
References 
1. Yong H, Chartier G, Quandt J. Modulating inflammation and neuropro-
tection in multiple sclerosis. J Neurosci Res. 2018; 96(6): 927–950, 
doi: 10.1002/jnr.24090, indexed in Pubmed: 28580582.
2. Lucas RM, Byrne SN, Correale J, et al. Ultraviolet radiation, vita-
min D and multiple sclerosis. Neurodegener Dis Manag. 2015; 
5(5): 413–424, doi: 10.2217/nmt.15.33, indexed in Pubmed: 
26477548.
3. Kubicka K, Pierzchała K. Concentration of 25(OH)D3 and calcium and 
phosphorus metabolism in patients suffering from relapsing-remitting 
multiple sclerosis. A pilot study. Neurologia i Neurochirurgia Polska. 
2013; 47(2): 126–130, doi: 10.5114/ninp.2013.34730.
4. Bell TD, Demay MB, Burnett-Bowie SAM. The biology and pathology 
of vitamin D control in bone. J Cell Biochem. 2010; 111(1): 7–13, 
doi: 10.1002/jcb.22661, indexed in Pubmed: 20506379.
5. Kępczyńska K, Zajda M, Lewandowski Z, et al. Bone metabolism and 
vitamin D status in patients with multiple sclerosis. Neurol Neurochir 
Pol. 2016; 50(4): 251–257, doi: 10.1016/j.pjnns.2016.04.010, inde-
xed in Pubmed: 27375138.
6. Bikle D. Vitamin D Metabolism, Mechanism of Action, and Clini-
cal Applications. Chemistry & Biology. 2014; 21(3): 319–329, 
doi: 10.1016/j.chembiol.2013.12.016.
7. Wacker M, Holick MF. Vitamin D - effects on skeletal and extraskeletal 
health and the need for supplementation. Nutrients. 2013; 5(1): 111–
148, doi: 10.3390/nu5010111, indexed in Pubmed: 23306192.
8. Lu M, Taylor BV, Körner H. Genomic Effects of the Vitamin D Re-
ceptor: Potentially the Link between Vitamin D, Immune Cells, and 
Multiple Sclerosis. Front Immunol. 2018; 9: 477, doi: 10.3389/fim-
mu.2018.00477, indexed in Pubmed: 29593729.
9. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihy-
droxyvitamin D(3) receptor in the immune system. Arch Biochem 
Biophys. 2000; 374(2): 334–338, doi: 10.1006/abbi.1999.1605, 
indexed in Pubmed: 10666315.
10. Tai Yu, Wang Q, Korner H, et al. Molecular Mechanisms of T Cells 
Activation by Dendritic Cells in Autoimmune Diseases. Front Phar-
macol. 2018; 9: 642, doi: 10.3389/fphar.2018.00642, indexed in 
Pubmed: 29997500.
11. Xie ZX, Zhang HL, Wu XJ, et al. Role of the immunogenic and tolerogen-
ic subsets of dendritic cells in multiple sclerosis. Mediators Inflamm. 
2015; 2015: 513295, doi: 10.1155/2015/513295, indexed in 
Pubmed: 25705093.
12. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, 
maturation, and function of human monocyte-derived dendritic cells. J 
Immunol. 2000; 164(9): 4443–4451, indexed in Pubmed: 10779743.
13. Bartosik-Psujek H, Tabarkiewicz J, Pocinska K, et al. Immuno-
modulatory effects of vitamin D on monocyte-derived dendritic 
cells in multiple sclerosis. Mult Scler. 2010; 16(12): 1513–1516, 
doi: 10.1177/1352458510379611, indexed in Pubmed: 20739336.
14. Unger WWJ, Laban S, Kleijwegt FS, et al. Induction of Treg by mono-
cyte-derived DC modulated by vitamin D3 or dexamethasone: dif-
ferential role for PD-L1. Eur J Immunol. 2009; 39(11): 3147–3159, 
doi: 10.1002/eji.200839103, indexed in Pubmed: 19688742.
15. van Halteren AGS, Tysma OM, van Etten E, et al. 1alpha,25-dihy-
droxyvitamin D3 or analogue treated dendritic cells modulate human 
autoreactive T cells via the selective induction of apoptosis. J Auto-
immun. 2004; 23(3): 233–239, doi: 10.1016/j.jaut.2004.06.004, 
indexed in Pubmed: 15501394.
16. Dankers W, Colin EM, van Hamburg JP, et al. Vitamin D in Autoim-
munity: Molecular Mechanisms and Therapeutic Potential. Front Im-
munol. 2016; 7: 697, doi: 10.3389/fimmu.2016.00697, indexed in 
Pubmed: 28163705.
17. Farias AS, Spagnol GS, Bordeaux-Rego P, et al. Vitamin D3 induces 
IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. 
CNS Neurosci Ther. 2013; 19(4): 269–277, doi: 10.1111/cns.12071, 
indexed in Pubmed: 23521914.
18. Chiuso-Minicucci F, Ishikawa LL, Mimura LA, et al. Treatment with 
Vitamin D/MOG Association Suppresses Experimental Autoimmune 
Encephalomyelitis. PLoS One. 2015; 10(5): e0125836, doi: 10.1371/
journal.pone.0125836, indexed in Pubmed: 25965341.
19. Mansilla MJ, Sellès-Moreno C, Fàbregas-Puig S, et al. Beneficial 
effect of tolerogenic dendritic cells pulsed with MOG autoantigen 
in experimental autoimmune encephalomyelitis. CNS Neurosci 
Ther. 2015; 21(3): 222–230, doi: 10.1111/cns.12342, indexed in 
Pubmed: 25403984.
20. Mansilla MJ, Contreras-Cardone R, Navarro-Barriuso J, et al. Cryopre-
served vitamin D3-tolerogenic dendritic cells pulsed with autoantigens 
as a potential therapy for multiple sclerosis patients. J Neuroinflam-
mation. 2016; 13(1): 113, doi: 10.1186/s12974-016-0584-9, inde-
xed in Pubmed: 27207486.
120
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 2
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
21. Zhang X, Zhou M, Guo Y, et al. 1,25-Dihydroxyvitamin D₃ Promotes 
High Glucose-Induced M1 Macrophage Switching to M2 via the VDR-
PPARγ Signaling Pathway. Biomed Res Int. 2015; 2015: 157834, 
doi: 10.1155/2015/157834, indexed in Pubmed: 25961000.
22. Kim EW, Teles RMB, Haile S, et al. Vitamin D status contributes to the 
antimicrobial activity of macrophages against Mycobacterium leprae. 
PLoS Negl Trop Dis. 2018; 12(7): e0006608, doi: 10.1371/journal.
pntd.0006608, indexed in Pubmed: 29965969.
23. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gam-
ma-mediated antimicrobial activity of human macrophages. Sci Transl 
Med. 2011; 3(104): 104ra102, doi: 10.1126/scitranslmed.3003045, 
indexed in Pubmed: 21998409.
24. Korf H, Wenes M, Stijlemans B, et al. 1,25-Dihydroxyvitamin D3 cur-
tails the inflammatory and T cell stimulatory capacity of macrophages 
through an IL-10-dependent mechanism. Immunobiology. 2012; 
217(12): 1292–1300, doi: 10.1016/j.imbio.2012.07.018, indexed in 
Pubmed: 22944250.
25. Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treat-
ment decreases macrophage accumulation in the CNS of mice with 
experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000; 
103(2): 171–179, indexed in Pubmed: 10696912.
26. Cantorna MT, Snyder L, Lin YD, et al. Vitamin D and 1,25(OH)2D regu-
lation of T cells. Nutrients. 2015; 7(4): 3011–3021, doi: 10.3390/
nu7043011, indexed in Pubmed: 25912039.
27. Sheikh V, Kasapoglu P, Zamani A, et al. Vitamin D3 inhibits the 
proliferation of T helper cells, downregulate CD4 T cell cytokines 
and upregulate inhibitory markers. Hum Immunol. 2018; 79(6): 
439–445, doi: 10.1016/j.humimm.2018.03.001, indexed in 
Pubmed: 29522785.
28. Boonstra A, Barrat FJ, Crain C, et al. 1alpha,25-Dihydroxyvitamin d3 
has a direct effect on naive CD4(+) T cells to enhance the develop-
ment of Th2 cells. J Immunol. 2001; 167(9): 4974–4980, indexed in 
Pubmed: 11673504.
29. Nashold FE, Hoag KA, Goverman J, et al. Rag-1-dependent cells are 
necessary for 1,25-dihydroxyvitamin D(3) prevention of experimen-
tal autoimmune encephalomyelitis. J Neuroimmunol. 2001; 119(1): 
16–29, indexed in Pubmed: 11525796.
30. Mayne CG, Spanier JA, Relland LM, et al. 1,25-Dihydroxyvitamin 
D3 acts directly on the T lymphocyte vitamin D receptor to inhib-
it experimental autoimmune encephalomyelitis. Eur J Immunol. 
2011; 41(3): 822–832, doi: 10.1002/eji.201040632, indexed in 
Pubmed: 21287548.
31. Pedersen LB, Nashold FE, Spach KM, et al. 1,25-dihydroxyvitamin 
D3 reverses experimental autoimmune encephalomyelitis by inhibit-
ing chemokine synthesis and monocyte trafficking. J Neurosci Res. 
2007; 85(11): 2480–2490, doi: 10.1002/jnr.21382, indexed in 
Pubmed: 17600374.
32. Mahon BD, Gordon SA, Cruz J, et al. Cytokine profile in patients with 
multiple sclerosis following vitamin D supplementation. J Neuroim-
munol. 2003; 134(1-2): 128–132, indexed in Pubmed: 12507780.
33. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial 
of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010; 
74(23): 1852–1859, doi: 10.1212/WNL.0b013e3181e1cec2, inde-
xed in Pubmed: 20427749.
34. O’Connell K, Sulaimani J, Basdeo SA, et al. Effects of vitamin D in 
clinically isolated syndrome and healthy control participants: A double-
blind randomised controlled trial. Mult Scler J Exp Transl Clin. 2017; 
3(3): 2055217317727296, doi: 10.1177/2055217317727296, in-
dexed in Pubmed: 28975037.
35. Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, et al. Short-term effect 
of high-dose vitamin D on the level of interleukin 10 in patients with 
multiple sclerosis: a randomized, double-blind, placebo-controlled 
clinical trial. Neuroimmunomodulation. 2015; 22(6): 400–404, 
doi: 10.1159/000439278, indexed in Pubmed: 26401986.
36. McGeachy MJ, Bak-Jensen KS, Chen Yi, et al. TGF-beta and IL-6 drive 
the production of IL-17 and IL-10 by T cells and restrain T(H)-17 
cell-mediated pathology. Nat Immunol. 2007; 8(12): 1390–1397, 
doi: 10.1038/ni1539, indexed in Pubmed: 17994024.
37. Cheng Y, Sun Li, Xie Z, et al. Diversity of immune cell types in multiple 
sclerosis and its animal model: Pathological and therapeutic impli-
cations. J Neurosci Res. 2017; 95(10): 1973–1983, doi: 10.1002/
jnr.24023, indexed in Pubmed: 28084640.
38. Babaloo Z, Aliparasti MR, Babaiea F, et al. The role of Th17 cells in pa-
tients with relapsing-remitting multiple sclerosis: interleukin-17A and 
interleukin-17F serum levels. Immunol Lett. 2015; 164(2): 76–80, 
doi: 10.1016/j.imlet.2015.01.001, indexed in Pubmed: 25625963.
39. Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclero-
sis: A Comprehensive Review. Neurol Ther. 2018; 7(1): 59–85, 
doi: 10.1007/s40120-017-0086-4, indexed in Pubmed: 29243029.
40. Chang JH, Cha HR, Lee DS, et al. 1,25-Dihydroxyvitamin D3 inhibits 
the differentiation and migration of T(H)17 cells to protect against 
experimental autoimmune encephalomyelitis. PLoS One. 2010; 
5(9): e12925, doi: 10.1371/journal.pone.0012925, indexed in 
Pubmed: 20886077.
41. Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ame-
liorates Th17 autoimmunity via transcriptional modulation of inter-
leukin-17A. Mol Cell Biol. 2011; 31(17): 3653–3669, doi: 10.1128/
MCB.05020-11, indexed in Pubmed: 21746882.
42. Jafarzadeh A, Azizi S, Arabi Z, et al. Vitamin D down-regulates the 
expression of some Th17 cell-related cytokines, key inflammatory 
chemokines, and chemokine receptors in experimental autoimmune 
encephalomyelitis. Nutritional Neuroscience. 2018: 1–13, doi: 10.10
80/1028415x.2018.1436237.
43. da Costa DS, Hygino J, Ferreira TB, et al. Vitamin D modulates different 
IL-17-secreting T cell subsets in multiple sclerosis patients. J Neuro-
immunol. 2016; 299: 8–18, doi: 10.1016/j.jneuroim.2016.08.005, 
indexed in Pubmed: 27725127.
44. Bhargava P, Sotirchos E, Eckstein C, et al. High-dose vitamin D supple-
mentation reduces IL-17-producing CD4+ Tcells and effector-memory 
CD4+ T-cells in multiple sclerosis patients (S38. 001). Neurology. 
2015; 84(14 Supplement): S38–001.
45. Smolders J, Thewissen M, Peelen E, et al. Vitamin D Status Is Posi-
tively Correlated with Regulatory T Cell Function in Patients with Mul-
tiple Sclerosis. PLoS ONE. 2009; 4(8): e6635, doi: 10.1371/journal.
pone.0006635.
46. Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modu-
lating effects of high dose vitamin D3 supplementation in multiple 
sclerosis. PLoS One. 2010; 5(12): e15235, doi: 10.1371/journal.
pone.0015235, indexed in Pubmed: 21179201.
47. Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, et al. Effect of high dose 
vitamin D intake on interleukin-17 levels in multiple sclerosis: a ran-
domized, double-blind, placebo-controlled clinical trial. J Neuroimmu-
nol. 2015; 285: 125–128, doi: 10.1016/j.jneuroim.2015.05.022, 
indexed in Pubmed: 26198928.
48. Muris AH, Smolders J, Rolf L, et al. SOLARIUM study group. Immune 
regulatory effects of high dose vitamin D supplementation in a ran-
domized controlled trial in relapsing remitting multiple sclerosis pa-
tients receiving IFNβ; the SOLARIUM study. J Neuroimmunol. 2016; 
121www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Halina Bartosik-Psujek, Marek Psujek, Vitamin D as an immune modulator in multiple sclerosis
300: 47–56, doi: 10.1016/j.jneuroim.2016.09.018, indexed in 
Pubmed: 27806875.
49. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and 
immune tolerance. Cell. 2008; 133(5): 775–787, doi: 10.1016/j.
cell.2008.05.009, indexed in Pubmed: 18510923.
50. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional sup-
pression by CD4+CD25+ regulatory T cells in patients with multi-
ple sclerosis. J Exp Med. 2004; 199(7): 971–979, doi: 10.1084/
jem.20031579, indexed in Pubmed: 15067033.
51. Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in 
multiple sclerosis patients. J Neurosci Res. 2005; 81(1): 45–52, 
doi: 10.1002/jnr.20522, indexed in Pubmed: 15952173.
52. Venken K, Hellings N, Thewissen M, et al. Compromised CD4+ 
CD25(high) regulatory T-cell function in patients with relapsing-re-
mitting multiple sclerosis is correlated with a reduced frequency of 
FOXP3-positive cells and reduced FOXP3 expression at the single-
cell level. Immunology. 2008; 123(1): 79–89, doi: 10.1111/j.1365-
-2567.2007.02690.x, indexed in Pubmed: 17897326.
53. Xie Z, Chen J, Zheng C, et al. 1,25-dihydroxyvitamin D -induced den-
dritic cells suppress experimental autoimmune encephalomyelitis by 
increasing proportions of the regulatory lymphocytes and reducing T 
helper type 1 and type 17 cells. Immunology. 2017; 152(3): 414–424, 
doi: 10.1111/imm.12776, indexed in Pubmed: 28617989.
54. Spanier J, Nashold F, Mayne C, et al. Vitamin D and estrogen synergy 
in Vdr-expressing CD4+ T cells is essential to induce Helios+FoxP3+ 
T cells and prevent autoimmune demyelinating disease. Journal 
of Neuroimmunology. 2015; 286: 48–58, doi: 10.1016/j.jneuro-
im.2015.06.015.
55. Sinha S, Boyden AW, Itani FR, et al. Immune regulation of multiple 
sclerosis by CD8+ T cells. Immunol Res. 2014; 59(1-3): 254–265, 
doi: 10.1007/s12026-014-8529-9, indexed in Pubmed: 24845461.
56. Machado-Santos J, Saji E, Tröscher AR, et al. The compartmental-
ized inflammatory response in the multiple sclerosis brain is com-
posed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 
2018; 141(7): 2066–2082, doi: 10.1093/brain/awy151, indexed in 
Pubmed: 29873694.
57. Lysandropoulos AP, Jaquiéry E, Jilek S, et al. Vitamin D has a direct 
immunomodulatory effect on CD8+ T cells of patients with early mul-
tiple sclerosis and healthy control subjects. J Neuroimmunol. 2011; 
233(1-2): 240–244, doi: 10.1016/j.jneuroim.2010.11.008, indexed 
in Pubmed: 21186064.
58. Disanto G, Morahan JM, Barnett MH, et al. The evidence for 
a role of B cells in multiple sclerosis. Neurology. 2012; 78(11): 
823–832, doi: 10.1212/WNL.0b013e318249f6f0, indexed in 
Pubmed: 22411958.
59. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihy-
droxyvitamin D3 on human B cell differentiation. J Immunol. 2007; 
179(3): 1634–1647, indexed in Pubmed: 17641030.
60. Lemire JM, Adams JS, Sakai R, et al. 1 alpha,25-dihydroxyvitamin D3 
suppresses proliferation and immunoglobulin production by normal 
human peripheral blood mononuclear cells. J Clin Invest. 1984; 74(2): 
657–661, doi: 10.1172/JCI111465, indexed in Pubmed: 6611355.
61. Heine G, Niesner U, Chang HD, et al. 1,25-dihydroxyvitamin D(3) 
promotes IL-10 production in human B cells. Eur J Immunol. 2008; 
38(8): 2210–2218, doi: 10.1002/eji.200838216, indexed in 
Pubmed: 18651709.
62. Rolf L, Muris AH, Hupperts R, et al. Illuminating vitamin D effects on B 
cells--the multiple sclerosis perspective. Immunology. 2016; 147(3): 
275–284, doi: 10.1111/imm.12572, indexed in Pubmed: 26714674.
63. Knippenberg S, Smolders J, Thewissen M, et al. Effect of vitamin 
D(3) supplementation on peripheral B cell differentiation and iso-
type switching in patients with multiple sclerosis. Mult Scler. 2011; 
17(12): 1418–1423, doi: 10.1177/1352458511412655, indexed in 
Pubmed: 21690147.
64. Peelen E, Rijkers G, Meerveld-Eggink A, et al. Relatively high serum 
vitamin D levels do not impair the antibody response to encapsu-
lated bacteria. Eur J Clin Microbiol Infect Dis. 2013; 32(1): 61–69, 
doi: 10.1007/s10096-012-1714-7, indexed in Pubmed: 22875191.
65. Knippenberg S, Peelen E, Smolders J, et al. Reduction in IL-10 pro-
ducing B cells (Breg) in multiple sclerosis is accompanied by a re-
duced naïve/memory Breg ratio during a relapse but not in remis-
sion. J Neuroimmunol. 2011; 239(1-2): 80–86, doi: 10.1016/j.jneu-
roim.2011.08.019, indexed in Pubmed: 21940055.
66. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin 
D2 in relapsing-remitting multiple sclerosis. Neurology. 2011; 77(17): 
1611–1618, doi: 10.1212/WNL.0b013e3182343274, indexed in 
Pubmed: 22025459.
67. Kampman MT, Steffensen LH, Mellgren SI, et al. Effect of vitamin D3 
supplementation on relapses, disease progression, and measures 
of function in persons with multiple sclerosis: exploratory outcomes 
from a double-blind randomised controlled trial. Mult Scler. 2012; 
18(8): 1144–1151, doi: 10.1177/1352458511434607, indexed in 
Pubmed: 22354743.
68. Soilu-Hänninen M, Aivo J, Lindström BM, et al. A randomised, double 
blind, placebo controlled trial with vitamin D3 as an add on treatment 
to interferon β-1b in patients with multiple sclerosis. J Neurol Neu-
rosurg Psychiatry. 2012; 83(5): 565–571, doi: 10.1136/jnnp-2011-
301876, indexed in Pubmed: 22362918.
69. Smolders J, Hupperts R, Vieth R, et al. High dose cholecalciferol (vi-
tamin D3) oil as add-on therapy in subjects with relapsing-remitting 
multiple sclerosis receiving subcutaneous interferon b-1a. In: Pre-
sented at the European Committee for Treatment and Research in 
Multiple Sclerosis conference. London, England, September 14–17, 
2016. Abstract S166.
70. Camu W, Pierrot-Deseilligny C, Hautecoeur P, et al. Cholecalciferol 
supplementation in relapsing multiple sclerosis patients treated with 
subcutaneous interferon beta-1a: a randomized, controlled trial. In: 
Presented at the European Committee for treatment and research in 
multiple sclerosis conference. London. England, September 14–17, 
2016.Abstract P750.
71. Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of Ad-
junct Low-Dose Vitamin D on Relapsing-Remitting Multiple Scle-
rosis Progression: Preliminary Findings of a Randomized Placebo-
Controlled Trial. Multiple Sclerosis International. 2012; 2012: 1–7, 
doi: 10.1155/2012/452541.
72. Mosayebi G, Ghazavi A, Ghasami K, et al. Therapeutic effect of vita-
min D3 in multiple sclerosis patients. Immunol Invest. 2011; 40(6): 
627–639, doi: 10.3109/08820139.2011.573041, indexed in 
Pubmed: 21542721.
73. Golan D, Halhal B, Glass-Marmor L, et al. Vitamin D supplementa-
tion for patients with multiple sclerosis treated with interferon-beta: 
a randomized controlled trial assessing the effect on flu-like symp-
toms and immunomodulatory properties. BMC Neurol. 2013; 13: 
60, doi: 10.1186/1471-2377-13-60, indexed in Pubmed: 23767916.
74. James E, Dobson R, Kuhle J, et al. The effect of vitamin D-related in-
terventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 
2013; 19(12): 1571–1579, doi: 10.1177/1352458513489756, inde-
xed in Pubmed: 23698130.
122
Neurologia i Neurochirurgia Polska 2019, vol. 53, no. 2
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
75. Zheng C, He L, Liu L, et al. The efficacy of vitamin D in multiple scle-
rosis: A meta-analysis. Mult Scler Relat Disord. 2018; 23: 56–61, 
doi: 10.1016/j.msard.2018.05.008, indexed in Pubmed: 29778041.
76. Bhargava P, Steele SU, Waubant E, et al. Multiple sclerosis patients 
have a diminished serologic response to vitamin D supplementation 
compared to healthy controls. Mult Scler. 2016; 22(6): 753–760, 
doi: 10.1177/1352458515600248, indexed in Pubmed: 26286698.
77. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D 
are independent risk factors for CNS demyelination. Neurology. 2011; 
76(6): 540–548, doi: 10.1212/WNL.0b013e31820af93d, indexed in 
Pubmed: 21300969.
78. Zivadinov R, Treu CN, Weinstock-Guttman B, et al. Interdependence 
and contributions of sun exposure and vitamin D to MRI mea-
sures in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 
84(10): 1075–1081, doi: 10.1136/jnnp-2012-304661, indexed in 
Pubmed: 23385850.
79. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune sys-
tem by UV radiation: more than just the effects of vitamin D? Nat Rev 
Immunol. 2011; 11(9): 584–596, doi: 10.1038/nri3045, indexed in 
Pubmed: 21852793.
80. Ullrich SE, Byrne SN. The immunologic revolution: photoimmunol-
ogy. J Invest Dermatol. 2012; 132(3 Pt 2): 896–905, doi: 10.1038/
jid.2011.405, indexed in Pubmed: 22170491.
81. Beecham AH, Patsopoulos NA, Xifara DK, et al. International Multiple 
Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control 
Consortium 2 (WTCCC2), International IBD Genetics Consortium (IIB-
DGC). Analysis of immune-related loci identifies 48 new susceptibility 
variants for multiple sclerosis. Nat Genet. 2013; 45(11): 1353–1360, 
doi: 10.1038/ng.2770, indexed in Pubmed: 24076602.
82. Mowry EM, Pelletier D, Gao Z, et al. Vitamin D in clinically isolat-
ed syndrome: evidence for possible neuroprotection. Eur J Neu-
rol. 2016; 23(2): 327–332, doi: 10.1111/ene.12844, indexed in 
Pubmed: 26518224.
83. Hancock REW, Haney EF, Gill EE. The immunology of host defence pep-
tides: beyond antimicrobial activity. Nat Rev Immunol. 2016; 16(5): 
321–334, doi: 10.1038/nri.2016.29, indexed in Pubmed: 27087664.
84. Cela EM, Friedrich A, Paz ML, et al. Time-course study of different in-
nate immune mediators produced by UV-irradiated skin: comparative 
effects of short and daily versus a single harmful UV exposure. Immu-
nology. 2015; 145(1): 82–93, doi: 10.1111/imm.12427, indexed in 
Pubmed: 25438991.
85. Bruhs A, Schwarz T, Schwarz A. A. Prevention and mitigation of ex-
perimental autoimmune encephalomyelitis by murine b-defensins via 
induction of regulatory T cells. F1000 - Post-publication peer review 
of the biomedical literature. 2015; 136: 173–181, doi: doi:10.1038/
JID. 2015.405.
86. Breuer J, Schwab N, Schneider-Hohendorf T, et al. Ultraviolet B light 
attenuates the systemic immune response in central nervous system 
autoimmunity. Ann Neurol. 2014; 75(5): 739–758, doi: 10.1002/
ana.24165, indexed in Pubmed: 24771567.
87. Kok LF, Marsh-Wakefield F, Marshall JE, et al. B cells are required for 
sunlight protection of mice from a CNS-targeted autoimmune attack. 
J Autoimmun. 2016; 73: 10–23, doi: 10.1016/j.jaut.2016.05.016, 
indexed in Pubmed: 27289166.
88. Breuer J, Loser K, Mykicki N, et al. Does the environment influence 
multiple sclerosis pathogenesis via UVB light and/or induction of 
vitamin D? Journal of Neuroimmunology. 2018, doi: 10.1016/j.jneu-
roim.2018.05.006.
